Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases.
OBJECTIVE
To examine differences in autoantibody response and immunogenetic background between patients with systemic sclerosis (SSc) and those with other autoimmune diseases who had serum anti-Th/To antibodies.


METHODS
Serum samples from 1048 Japanese patients with various autoimmune diseases were screened for anti-Th/To antibodies using RNA and protein immunoprecipitation assays. The reactivity to RNase P subunits was examined by immunoprecipitating (35)S labelled recombinant Rpp38, Rpp30, and hPop1 produced by in vitro transcription and translation. HLA-DRB1, DQB1, and DPB1 alleles were identified using a polymerase chain reaction followed by a restriction fragment length polymorphism assay.


RESULTS
Serum anti-Th/To antibodies were detected in 14 of 303 patients with SSc and seven of 745 patients without SSc (4.6% v 0.9%; p=0.0003). Similar percentages of patients with and without SSc showed immunoreactivity to Rpp38 and Rpp30, but more patients with SSc than patients without SSc showed a reactivity to hPop1 (93% v 14%; p=0.002). In patients with anti-Th/To antibodies DRB1*1502 or *0802 was detected more often, and the DRB1*0405-DQB1*0401 haplotype less often in patients with SSc than in patients without SSc (79% v 14%, p=0.02, and 7% v 71%, p=0.01, respectively).


CONCLUSIONS
Anti-Th/To antibodies were detected in a small proportion of autoimmune patients lacking clinical features related to SSc. A close relationship between disease expression and anti-hPop1 reactivity as well as HLA class II alleles in anti-Th/To positive patients suggests that the process of anti-Th/To antibody production may be different between patients with and those without SSc.
Kuwana
M
M
Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. kuwanam@sc.itc.keio.ac.jp
Kimura
K
K
Hirakata
M
M
Kawakami
Y
Y
Ikeda
Y
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000276:immunology; D029742:Caenorhabditis elegans Proteins; D002503:Centromere / Q000276:immunology; D004268:DNA-Binding Proteins / Q000276:immunology; D004722:Endoribonucleases / Q000276:immunology; D005260:Female; D006682:HLA-DP Antigens / Q000032:analysis; D059868:HLA-DP beta-Chains; D006683:HLA-DQ Antigens / Q000032:analysis; D059866:HLA-DQ beta-Chains; D006684:HLA-DR Antigens / Q000032:analysis; D059811:HLA-DRB1 Chains; D006239:Haplotypes; D006609:High Mobility Group Proteins / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D029701:Saccharomyces cerevisiae Proteins; D012595:Scleroderma, Systemic / Q000276:immunology*
D001323:Autoantibodies; D001324:Autoantigens; D029742:Caenorhabditis elegans Proteins; D004268:DNA-Binding Proteins; D006682:HLA-DP Antigens; D059868:HLA-DP beta-Chains; C071170:HLA-DPB1 antigen; D006683:HLA-DQ Antigens; D059866:HLA-DQ beta-Chains; C069051:HLA-DQB1 antigen; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D006609:High Mobility Group Proteins; D029701:Saccharomyces cerevisiae Proteins; C071036:To autoantigen; C096787:pop-1 protein, C elegans; D004722:Endoribonucleases; C108353:RPP1 protein, S cerevisiae